ZPD A/S finalizes KDMF and approval in Korea with its branded Chondroitin Sulfate - ScanDroitin™.
The Korean Food and Drug Safety Agency has approved ScanDroitin™ Chondroitin Sulfate as an API with a registered Korean drug master file. ScanDroitin™ is a uniquely manufactured ingredient obtaining the industry’s highest level of purity with a proprietary process which is totally organic solvent free.
In cooperation with South Korean partner CKD BiO Corp. (Chong Kun Dang Biotechnology), ScanDroitin™ will be available for interested companies looking for a European source Chondroitin Sulfate. CKD now holds the exclusive distribution rights to ScanDroitin™ in South Korea.
Frank Marek, Managing Director of ZPD A/S, commented: “We are pleased to have finalized our registration in cooperation with CKD BiO Corp, and now look forward to offering our ScanDroitin™ solutions to the South Korean market together with a strong and reliable partner.”
Adding another milestone by achieving the registration in, what is considered by many, to be one of the toughest regulatory markets worldwide, this was all made possible due to the dedicated teams of experts from ZPD and CKD who handled all the necessary steps in the registration process.
“Reaching this important milestone, we are ready to explore further opportunities in markets with tough regulatory requirements and entrench ZPD as one of the main players globally, for the production and supply of innovative, high-quality ingredients and APIs aimed mainly at the market for joint health.
Our dedicated team of experts stand ready to handle new business opportunities and are already active in supporting partners for final dossier registrations with ScanDroitin™”, said Samer Abou-Houssein, Head of Sales at ZPD A/S.